20.5 C
New York
Thursday, June 18, 2026

Tag: screening

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance...

Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030

"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector" BOSTON, Aug. 5, 2025 /PRNewswire/ --...

Quantifind Joins Forces with OpenSanctions to Deliver the Gold Standard in Sanctions Compliance

PALO ALTO, Calif., Aug. 5, 2025 /CNW/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they...

Quantifind Joins Forces with OpenSanctions to Deliver the Gold Standard in Sanctions Compliance

PALO ALTO, Calif., Aug. 5, 2025 /PRNewswire/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they...

Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology Consulting

The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of...

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

The Hidden Lung Infection Impacting Millions: World NTM Day Puts Spotlight on Awareness

With Annual NTM Case Rates Rising, Patients and Providers Are Urged to Recognize the Symptoms and Risks MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the...

United Imaging Teases Multi-modality “Provider Success” Product Launches at AHRA 2025

The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting in Las Vegas. HOUSTON, Aug. 3, 2025...

Bitcoin Swift Launches Stage 3 Presale With AI-Driven Proof-of-Yield Rewards System

LUXEMBOURG , Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift, a blockchain protocol combining Proof-of-Work (PoW), Proof-of-Stake (PoS), and an AI-powered Proof-of-Yield (PoY) mechanism, has officially entered Stage 3 of its presale. The platform is offering tokens at $3 during this limited 64-day window, with a scheduled increase to $4 in the next stage and a confirmed launch price of $15.

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report

ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsScreening